Deborah H. Telman, Executive Vice President of Corporate Affairs and General Counsel at Gilead Sciences (GILD), has demonstrated a clear selling bias in her recent insider transactions, according to SEC Form 4 filings. Over her 31 reported trades, she has sold $7.39 million worth of GILD stock while purchasing $3.51 million, with all three of her most recent transactions being sales. The bulk of her disposals occurred on November 12, 2025, when she executed multiple sales totaling $6.53 million, including a single transaction valued at $4.40 million. These disposals were accompanied by smaller derivative transactions marked as "M" (likely option exercises or conversions), suggesting a structured unwinding of positions.
Prior to the November 2025 sales, Telman's activity was mixed but leaned toward smaller, periodic sales. Between January 2025 and October 2025, she conducted several transactions labeled as "F" (likely tax-related or planned sales), ranging from $17,404 to $444,233. Notably, she has not reported any open-market purchases since at least 2024, with her only acquisitions likely tied to equity awards (indicated by "A" coded transactions with $0 value). The absence of recent buys and the concentration of high-value sales in late 2025 point to a sustained reduction in her GILD holdings rather than routine portfolio rebalancing.
AI-assisted summary